Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C

Annals of Internal Medicine

Volumn 129, Issue 2, 1998, Pages 94-99

  Imai, Yasuharu ^a   Kawata, Sumio ^a   Tamura, Shinji ^a   Yabuuchi, Iwao ^a   Noda, Shuzo ^a   Inada, Masami ^a,b   Maeda, Yuichi ^a,c   Shirai, Yasuhiro ^a,d   Fukuzaki, Takaaki ^a,e   Kaji, Itaru ^a,f   Ishikawa, Hideki ^a,f   Matsuda, Yukihiko ^a   Nishikawa, Masahiro ^a   Seki, Kouichi ^a,g   Matsuzawa, Yuji ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b TOYONAKA MUNICIPAL HOSPITAL   (Japan)

^c Kawanishi City General Hospital   (Japan)

^d Izumisano Municipal Hospital   (Japan)

^e Department of Internal Medicine   (Japan)

^f OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^g Hyogo Prefectural Nishinomiya Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; RECOMBINANT ALPHA2A INTERFERON;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER PREVENTION; CHRONIC HEPATITIS; DRUG EFFECT; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; IMMUNOTHERAPY; LIVER BIOPSY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0343111507     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-129-2-199807150-00005     Document Type: Article

References (31)

1. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology. 1992;15: 948-63.
2. Simonetti RG, Camma C, Fiorello F, Politi F, D'Amlco G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci. 1991;36:962-72.
3. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res. 1987;47:4967-72.
4. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 1993;18:47-53.
5. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Semin Liver Dis. 1995;15:64-9.
6. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359-62.
7. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989;244:362-4.
8. Diodati G, Tagger A, Bonnei P, Ribero ML, Drago C, Cavelletto D, et al. Antibody to hepatitis C virus in cryptogenic chronic liver disease. J Med Virol. 1991;35:151-4.
9. Bruix J, Barrera JM, Calvet X, Ercilla G, Corta J, Sanchez-Tapias JM, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet. 1989;2:1004-6.
10. Simonetti RG, Camma C, Fiorello F, Cottone M, Rapicetta M, Marino L, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med. 1992;116: 97-102.
11. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797-801.
12. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991;325:675-80.
13. Nishioka K, Watanabe J, Furuta S, Tanaka E, Iino S, Suzuki H, et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer. 1991;67:429-33.
14. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med. 1989;321:1501-6.
15. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner JG, et al. Recombinant interferon alfa therapy for chronic hep-atitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321:1506-10.
16. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, et al. Randomized trial comparing three different regimens of alpha-2a interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology. 1995;22:700-6.
17. Shindo M, Di Bisceglie AM, Cheung L, Shih JW, Cristiano K, Feinstone SM, et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med. 1991;115:700-4.
18. David E, Pucci A, Palladin D, Saracco G, Garello E, Pintus C, et al. Histologic changes in liver biopsy specimens produced by recombinant interferon alpha-2b therapy for chronic non-A, non-B viral hepatitis. A randomized controlled trial. Am J Clin Pathol. 1992;98:397-401.
19. Manabe N, Chevallier M, Chossegros P, Causse X, Guerret S, Trepo C, et al. Interferon alpha-2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology. 1993;18: 1344-9.
20. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 1996;24:778-89.
21. Murakami R, Tsukuma H, Ubukata T, Nakanishi K, Fujimoto I, Kawashima T, et al. Estimation of validity of mass screening program for gastric cancer in Osaka, Japan. Cancer. 1990;65:1255-60.
22. Murakami R, Tsukuma H, Kanamori S, Imanishi K, Otani T, Nakanishi K, et al. Natural history of colorectal polyps and the effect of polypectomy on occurrence of subsequent cancer, Int J Cancer. 1990;46:159-64.
23. Kato N, Yokosuka O, Omata M, Hosoda K, Ohto M. Detection of hepatic C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. J Clin Invest. 1990;86:1764-7.
24. Yamada G, Takatani M, Kishi F, Takahashi M, Doi T, Tsuji T, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology. 1995;22:1351-4.
25. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994; 19:1513-20.
26. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1: 431-5.
27. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie AM, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;315: 1575-8.
28. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects if interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051-5.
29. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 1996;24:141-7.
30. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 1997;25:754-8.
31. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1997;27:201-5.